Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Dose Ranging, Randomized, Double Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis (PBC) With or Without an Inadequate Response to Ursodeoxycholic Acid (UDCA)

Next Previous
X
Search
Trial Profile

A Phase 2 Dose Ranging, Randomized, Double Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis (PBC) With or Without an Inadequate Response to Ursodeoxycholic Acid (UDCA)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 21 Sep 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs EDP 305 (Primary)
  • Indications Primary biliary cirrhosis
  • Focus Therapeutic Use
  • Acronyms INTREPID
  • Sponsors Enanta Pharmaceuticals

    • Most Recent Events

    • 05 Jun 2020 Status changed from active, no longer recruiting to completed.
    • 06 May 2020 Primary endpoint has not been met. (Proportion of subjects with at least 20% reduction in ALP from pre-treatment value or normalization of ALP at Week 12)
    • 06 May 2020 According to an Enanta Pharmaceuticals media release, Clinical Professor, Elson S. Floyd College of Medicine, Washington State University, the Principal Investigator for the study

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top